Tabrecta (capmatinib) — Medica
Non-small cell lung cancer (NSCLC)
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient meets ONE of the following: (i) mesenchymal epithelial transition (MET) exon 14 skipping mutation as detected by an approved test OR (ii) high-level MET amplification as detected by an approved test
Approval duration
1 year